The Business Times

Novartis

Energy Efficiency National PartnershipESG

Novartis Singapore steps up in the race to net zero

The Swiss drugmaker will pay US$48 per share in cash for the New York-based biotech, which is developing a promising treatment to reduce systemic inflammation, a major driver of cardiovascular disease. 
Consumer & Healthcare

Novartis to buy US biotech Tourmaline Bio for US$1.4 billion

Novartis joins a growing number of multinational drug companies to announce investments in the US this year.
Consumer & Healthcare

Novartis pledges US$23 billion US investment as tariffs loom

FILE PHOTO: The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
Consumer & Healthcare

Novartis to acquire Anthos for up to US$3.1 billion

Logos sit above windows at Novartis AG's headquarters in Basel, Switzerland, on Tuesday, July, 16, 2013. Novartis raised its profit and sales forecasts as generic competition for the Diovan blood-pressure medicine failed to materialize in the U.S. Photographer: Gianluca Colla/Bloomberg
Companies & Markets

Novartis to buy radiology specialist Mariana Oncology for US$1 billion

Deputy Prime Minister Heng Swee Keat at the groundbreaking ceremony for Novartis' groundbreaking ceremony for its biopharmaceutical plant expansion.
Singapore

Novartis invests US$256 million to expand Singapore plant

Novartis will offer shareholders 68 euros per share in cash and take MorphoSys private after the deal.
Companies & Markets

Novartis to acquire cancer-focused MorphoSys for 2.7 billion euros

FILE PHOTO: The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
Companies & Markets

Novartis signs gene therapy deal with Voyager for US$100 million upfront

FILE PHOTO: The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
Companies & Markets

Novartis lifts 2023 earnings forecast for third time

Richard Saynor, chief executive officer of Sandoz Group, speaking during the drugmaker's listing ceremony in Switzerland on Oct. 4.
International

Novartis spinoff Sandoz starts trading as standalone drugmaker

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More